Magenta Therapeutics Selected as “Hottest Early Stage Startup” in Healthcare in New England Venture Capital Association’s 2017 NEVY Awards

CAMBRIDGE, Mass. – May 18, 2017 – Magenta Therapeutics announced that it has been named the winner of the “Hottest Startup” in the healthcare section at the 2017 NEVY Awards presented by the New England Venture Capital Association. This was the fifth annual event for the NEVY Awards to honor the best and the brightest in the region’s technology and healthcare startup ecosystem.

The Hottest Startup award honors companies that are “setting the world on fire,” and have received funding within the past year. In selecting Magenta for the Hottest Startup award, the NEVY judges recognized the company’s mission to improve and expand the use of curative stem cell transplantation for more patients, including those with autoimmune diseases, genetic blood disorders, and cancers.

“We are honored to receive this award which recognizes Magenta’s rapid progress since launching in late 2016,” said Jason Gardner, D.Phil., chief executive officer, president, and cofounder of Magenta Therapeutics. “We have recruited a strong team, who are building a new platform in stem cell science that aims to transform transplant medicine. This an exciting time, and while we still have a long way to go, our team are moving forward with courage, commitment and excellence to make a difference for patients with autoimmune disorders, genetic diseases and cancer.”

About Magenta Therapeutics
Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune and blood-based diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to stem cell therapies to create patient benefits. Founded by internationally recognized leaders in stem cell transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit